Table 3. Clinical and hematologic... | American Society of Hematology

Table 3.

Clinical and hematologic characteristics of patients with chronic idiopathic thrombocytopenic purpura

Case no.	Age/sex	Prior therapy	Duration of disease, mo	Platelet count before therapy, × 10⁹/L^3-150	Platelet counts after therapy, × 10⁹/L						Response duration, wk	Subsequent therapy
Case no.	Age/sex	Prior therapy	Duration of disease, mo	Platelet count before therapy, × 10⁹/L^3-150	Wk 1	Wk 2	Wk 3	Wk 4	Wk 8	Wk 12	Response duration, wk	Subsequent therapy
1	51/M	P, Ig, DXM	15	12	25	28	27	35	32	13	—	P, VC
2	44/F	P, Ig	22	6	65	113	238	301	347	256	108+	—
3	27/F	P, Ig	17	19	107	145	127	139	72	22	6	Rtx, P, VC
4	52/M	P, Ig	12	16	35	27	29	25	31	24	94+	—
5	74/F	P, Ig, V, Cy	28	4	73	187	290	331	268	193	49	Rtx
6	45/M	P, Ig, S	35	11	33	51	64	90	69	22	5	Rtx, P
7	32/F	P, Ig, V, DXM	37	8	15	18	17	21	19	13	—	S
8	55/M	P, Ig, S, Cy	41	25	31	58	44	40	39	21	—	VC
9	48/F	P, Ig, V, S	33	7	19	20	18	27	30	17	—	P
10	36/F	P, Ig, S, DXM	39	14	17	5	14	12	17	8	—	P
11	57/F	P, Ig, VC	10	9	34	75	67	81	66	73	29	Rtx, V, P
12	24/F	P, Ig	13	24	22	34	38	27	15	21	—	S
13	22/M	P, Ig	17	9	25	40	48	62	44	19	3	VC
14	25/F	P, Ig, V, DXM	25	13	105	218	339	356	423	282	83+	—
15	46/F	P, Ig, S	34	21	25	18	39	46	33	10	—	V, VC
16	53/M	P, Ig, DXM	13	15	56	43	31	37	35	19	—	S
17	64/F	P, Ig, DXM	11	19	35	27	43	40	32	12	—	Ig, S
18	69/M	P, Ig, DXM	17	3	27	13	16	23	18	9	—	S
19	29/F	P, Ig, V, S, Cy	39	11	59	212	234	395	372	285	45+	—
20	57/F	P, Ig, VC, S	44	7	49	81	103	87	31	13	2	P, Cy
21	35/M	P, Ig, DXM, Cy	51	10	25	32	28	34	41	19	—	P
22	28/F	P, Ig, DXM	19	21	69	112	84	95	72	85	30	P
23	59/F	P, Ig, S, aRh	56	13	18	13	16	20	19	24	—	P
24	44/F	P, Ig	9	18	25	33	29	41	37	33	19+	—
25	61/M	P, Ig, DXM	12	17	72	76	58	45	47	31	14+	—

Case no.	Age/sex	Prior therapy	Duration of disease, mo	Platelet count before therapy, × 10⁹/L^3-150	Platelet counts after therapy, × 10⁹/L						Response duration, wk	Subsequent therapy
Case no.	Age/sex	Prior therapy	Duration of disease, mo	Platelet count before therapy, × 10⁹/L^3-150	Wk 1	Wk 2	Wk 3	Wk 4	Wk 8	Wk 12	Response duration, wk	Subsequent therapy
1	51/M	P, Ig, DXM	15	12	25	28	27	35	32	13	—	P, VC
2	44/F	P, Ig	22	6	65	113	238	301	347	256	108+	—
3	27/F	P, Ig	17	19	107	145	127	139	72	22	6	Rtx, P, VC
4	52/M	P, Ig	12	16	35	27	29	25	31	24	94+	—
5	74/F	P, Ig, V, Cy	28	4	73	187	290	331	268	193	49	Rtx
6	45/M	P, Ig, S	35	11	33	51	64	90	69	22	5	Rtx, P
7	32/F	P, Ig, V, DXM	37	8	15	18	17	21	19	13	—	S
8	55/M	P, Ig, S, Cy	41	25	31	58	44	40	39	21	—	VC
9	48/F	P, Ig, V, S	33	7	19	20	18	27	30	17	—	P
10	36/F	P, Ig, S, DXM	39	14	17	5	14	12	17	8	—	P
11	57/F	P, Ig, VC	10	9	34	75	67	81	66	73	29	Rtx, V, P
12	24/F	P, Ig	13	24	22	34	38	27	15	21	—	S
13	22/M	P, Ig	17	9	25	40	48	62	44	19	3	VC
14	25/F	P, Ig, V, DXM	25	13	105	218	339	356	423	282	83+	—
15	46/F	P, Ig, S	34	21	25	18	39	46	33	10	—	V, VC
16	53/M	P, Ig, DXM	13	15	56	43	31	37	35	19	—	S
17	64/F	P, Ig, DXM	11	19	35	27	43	40	32	12	—	Ig, S
18	69/M	P, Ig, DXM	17	3	27	13	16	23	18	9	—	S
19	29/F	P, Ig, V, S, Cy	39	11	59	212	234	395	372	285	45+	—
20	57/F	P, Ig, VC, S	44	7	49	81	103	87	31	13	2	P, Cy
21	35/M	P, Ig, DXM, Cy	51	10	25	32	28	34	41	19	—	P
22	28/F	P, Ig, DXM	19	21	69	112	84	95	72	85	30	P
23	59/F	P, Ig, S, aRh	56	13	18	13	16	20	19	24	—	P
24	44/F	P, Ig	9	18	25	33	29	41	37	33	19+	—
25	61/M	P, Ig, DXM	12	17	72	76	58	45	47	31	14+	—

M indicates male; P, prednisone; Ig, intravenous immunoglobulins; VC, vitamin C; DXM, high-dose dexamethasone; F, female; Rtx, rituximab; V, vincristine; Cy, pulse cyclophosphamide; S, splenectomy; aRh, anti-Rh immunoglobulin.

F3-150

Nadir platelet count before rituximab.

View Large

This Feature Is Available To Subscribers Only